Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has received Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for the inspection carried out by them at our Formulation Facility at Panelav during the . period from March 12, 2018 to March 20, 2018.

The stock had outperformed the market over the past one month till Jun. 14, 2018, rising 0.39% compared with the Sensex's 0.12% rise. It underperformed the market in past one quarter, declining 9.48% as against 5.21% rise in the Sensex.

Shares of the company gained Rs 6.85, or 1.35%, to trade at Rs 513.40. The total volume of shares traded was 4,704 at the BSE (10.24 a.m., Friday).